Internal Medicine, Infectious Disease · Nashville, TN
NPI
1437441847
Since 2011
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
330 23rd Ave N Ste 300
Nashville, TN, 37203
Phone (615) 342-6010
Groups this clinician bills Medicare through
Medicare paid, 2024
$74K
824 services
Medicare patients, 2024
225
Average age 72
Drug cost, 2024
$553K
999 prescriptions
Company payments, 2025
$1,869
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul A Bryant was code 99233 (hospital e&m - subsequent), 329 times for 128 patients. In total Paul A Bryant billed 824 services in 17 codes, and Medicare paid $74K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 329 | 128 | $87.43 | $29K |
| 99232 Hospital E&M - Subsequent | Facility | 188 | 94 | $57.86 | $11K |
| 99223 Hospital E&M - Initial | Facility | 123 | 109 | $126.31 | $16K |
| 99214 Office E&M - Established | Office | 72 | 48 | $84.27 | $6,068 |
| 99291 Critical Care E&M | Facility | 48 | 15 | $156.67 | $7,520 |
| 99204 Office E&M - New | Office | 21 | 21 | $122.89 | $2,581 |
| 99231 Hospital E&M - Subsequent | Facility | 13 | 13 | $36.35 | $473 |
| 99213 Office E&M - Established | Office | 13 | 12 | $66.78 | $868 |
By year: 2022 $78K for 873 services; 2023 $75K for 815 services; 2024 $74K for 824 services.
Medicare prescription drug claims, 2024
In 2024, the drug Paul A Bryant prescribed most often to Medicare patients was Cephalexin, with 107 prescriptions and refills. In total Paul A Bryant wrote 999 Medicare prescriptions that cost $553K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cephalexin Generic | 107 | 127 | 23 | $923 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 84 | 102 | 16 | $1,009 |
| Ethambutol Hcl Generic | 54 | 74 | Under 11 | $2,804 |
| Azithromycin Generic | 51 | 75 | Under 11 | $1,169 |
| Doxycycline Monohydrate Generic | 49 | 70 | 16 | $3,401 |
| Amoxicillin Generic | 45 | 59 | Under 11 | $511 |
| Rifampin Generic | 44 | 67 | Under 11 | $2,964 |
| Vancomycin Hcl Generic | 41 | 41 | 13 | $5,457 |
| Daptomycin Generic | 41 | 41 | Under 11 | $25K |
| Ciprofloxacin Hcl Generic | 40 | 41 | 11 | $398 |
| Ceftriaxone Ceftriaxone Sodium | 39 | 39 | Under 11 | $1,033 |
| Zerbaxa Ceftolozane/Tazobactam | 36 | 36 | Under 11 | $213K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 34 | 34 | Under 11 | $133K |
| Cefazolin Sodium Generic | 31 | 31 | Under 11 | $807 |
| Doxycycline Hyclate Generic | 28 | 28 | Under 11 | $586 |
Brand drugs: 136 claims; generic drugs: 863 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul A Bryant $1,869 ($1,869 in general payments such as food, travel and fees) from 18 companies. The largest payer was Abbvie Inc. with $429.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 29 | $429 |
| Insmed, Inc. INSM | 17 | $317 |
| Cumberland Pharmaceuticals, Inc. CPIX | 22 | $274 |
| Merck Sharp & Dohme LLC MRK | 7 | $180 |
| Gilead Sciences, Inc. GILD | 14 | $169 |
| Janssen Biotech, Inc. JNJ | 4 | $82.66 |
| Ardelyx, Inc. ARDX | 3 | $62.18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $57.68 |
| ViiV Healthcare Company GSK | 2 | $49.25 |
| Novo Nordisk Inc NVO | 2 | $45.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.